 in the U.S. And if they're unable to, it actually may stifle innovation around the world because they don't see the return on investment to bring it into other countries. Well, we're going to continue talking about this after a break, and we're especially going to focus on some movement, I think, in the FDA and in looking at this in a different way. And I want both of you to weigh in on that. But